Fingolimod-associated macular edema

  title={Fingolimod-associated macular edema},
  author={Nieraj Jain and M. Tariq Bhatti},
  pages={672 - 680}
Fingolimod (FTY-720), a sphingosine-1-phosphate receptor modulator, is the first US Food and Drug Administration (FDA)–approved oral agent for the treatment of relapsing forms of multiple sclerosis (MS). Two recent phase III clinical studies (TRANSFORMS [Trial Assessing Injectable Interferon vs FTY720 Oral in RRMS] and FREEDOMS [FTY720 Research Evaluating Effects of Daily Oral Therapy in MS]) demonstrated a significant reduction in the annualized relapse rate in patients with relapsing… 

Figures and Tables from this paper

Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis

Fingolimod is an effective treatment for relapsing MS and its oral route of administration may be preferred by some, and it is generally well tolerated but requires diligence in patient selection and monitoring.

Fingolimod Associated Bilateral Cystoid Macular Edema—Wait and See?

The excellent therapeutic response in this patient may justify the use of anti-VEGF-A agents in combination with cessation of fingolimod to achieve fast resolution of FAME and to prevent visual deficits, particularly in bilateral FAME.

Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications

FAME may be managed with nonsteroidal anti-inflammatory eye drops without discontinuation of fingolimod in appropriate patient monitored with close follow up.

Acute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis

The case of a 34-year-old male with relapsing-remitting multiple sclerosis, who developed acute anterior uveitis on day 5 of fingolimod treatment, is reported.

The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis

The mechanisms of action of these three oral disease-modifying drugs are elucidate, including potential activities within the central nervous system, and their efficacy, safety, and tolerability are compared as a practical guideline for their use.

Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations.

Fingolimod treatment in multiple sclerosis leads to increased macular volume

Initiation of fingolimod in MS is associated with a modest, relatively rapid increase in macular volume, and that of the matched reference cohort of patients with MS never exposed to the drug.

Severe early bilateral macular edema following fingolimod therapy.

Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events

The present review lists the non-cardiologic adverse events that all neurologists prescribing fingolimod should be aware of, and its first hours of use are associated with related to S1P receptors in the heart.



Oral fingolimod (FTY720) for relapsing multiple sclerosis.

In this proof-of-concept study, fingolimod reduced the number of lesions detected on MRI and clinical disease activity in patients with multiple sclerosis and both measures decreased in patients who switched from placebo to fingolIMod.

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.

Randomized Controlled Trial of FTY720 Versus MMF in De Novo Renal Transplantation

This one-year, multicenter, randomized, phase III study in 696 de novo renal transplant patients compared FTY720 5 mg plus reduced-dose cyclosporine (RDC) with mycophenolate mofetil (MMF) plus FDC and found that the associated lower creatinine clearance indicated that FTY 720 combined with cyclospora provided no benefit over standard care.

FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1‐Year, Randomized Controlled Trial in Europe and Australasia

  • M. SalvadoriK. Budde S. Aradhye
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2006
FTY720 is a novel immunomodulator investigated in de novo renal transplantation and other therapeutic areas including multiple sclerosis and provided comparable rejection prophylaxis over 12 months versus MMF; however, FTY720 5.0 mg did not support a 50% reduction in cyclosporine exposure.

A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis

Although the differences between the groups decreased with time, at six months the group that received intravenous methylprednisolone still had slightly better visual fields, contrast sensitivity, and color vision but not better visual acuity.

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.

Intravenous methylprednisolone followed by oral prednisone speeds the recovery of visual loss due to optic neuritis and results in slightly better vision at six months.

Acute Inflammatory Demyelinating Optic Neuritis: Evidence-Based Visual and Neurological Considerations

ON is the best studied CIS and the visual prognosis is excellent in most cases regardless of whether the patient is treated with corticosteroids or not, and intravenous methylprednisolone accelerates visual recovery from ON but has no impact on long-term visual outcome.